has requested that the U.S. Food and Drug Administration speed up the review process for new drug, called tafamidis, The Day reported.
The FDA has agreed to make the pill a priority, which, according to the article, has
"already has received approval in the European Union for its ability to delay neurological impairment."
The Day reported that the drug application to be reviewed is for "an experimental pill to treat Transthyretin Familial Amyloid Polyneuropathy, a rare neurodegenerative disease also known as TTR-FAP."
